
Please try another search
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Name | Age | Since | Title |
---|---|---|---|
Quan Dong Nguyen | - | 2022 | Member of Scientific Advisory Board |
Anat Loewenstein | - | 2022 | Member of Scientific Advisory Board |
Pablo Villoslada | - | 2022 | Member of Scientific Advisory Board |
Geraldine O’Keeffe | 56 | - | Independent Director |
Christophe Baudouin | 62 | 2022 | Member of Scientific Advisory Board |
Arshad M. Khanani | - | 2022 | Member of Scientific Advisory Board |
Christina M. Ackermann | 58 | - | Independent Director |
Peter K. Kaiser | - | 2022 | Member of Scientific Advisory Board |
Martijn Kleijwegt | 68 | - | Independent Director |
Kuldev Singh | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review